June 2022 Newsletter

The September 2022 issue of the NMD4C newsletter is now available!

Read about the approved Area of Focused Competency in Neuromuscular Medicine, a new Clinical Trial Finder Tool from Defeat Duchenne Canada, and we share the launch of our new video series "Meet the Fellows"! Plus community events, new research, member spotlights and more!

View the June 2022 newsletter.

Sign up for future issues of the NMD4C newsletter.

Meet the Fellows Video Series

Area of Focused Competency in Neuromuscular Medicine Approved by Royal College of Physicians and Surgeons of Canada

Defeat Duchenne Canada Launches New Clinical Trial Finder Tool

New Research from NMD4C Participants

Randomized Phase 2 Study of ACE-083, a Muscle-Promoting Agent, in Facioscapulohumeral Muscular Dystrophy

  • Dr. Jeffrey Statland with Drs. Lawrence Korngut & Craig Campbell  (NMD4C) as co-authors

 

Onasemnogene abeparvovec for the treatment of spinal muscular atrophy

  • Dr. Hugh McMillan (NMD4C).

 

Electronic alerts and a care bundle for acute kidney injury - an Australian cohort study

  • Dr. Sradha Kotwal, with Dr. Craig Campbell (NMD4C) as a co-author.

 

Case Report: Advanced Skeletal Muscle Imaging in S-Adenosylhomocysteine Hydrolase Deficiency and Further Insight Into Muscle Pathology

  • Dr. Danijela Petković Ramadža with Dr. Hanns Lochmüller (NMD4C) as a co-author.

 

Central and peripheral delivered AAV9-SMN are both efficient but target different pathomechanisms in a mouse model of spinal muscular atrophy

  • Aoife Reilly, with Dr. Rashmi Kothary (NMD4C) as a co-author.

 

Participation and Functional Independence in Adults With Recessive Spastic Ataxia of Charlevoix-Saguenay

  • Samar Muslemani, with Drs. Bernard Brais & Cynthia Gagnon (NMD4C) as co-authors.

Join  the NMD4C